The dispersible child-friendly TB fixed-dose combinations (FDCs) produced by Macleods Pharmaceuticals Ltd. have both received WHO prequalification (PQ):
- For the intensive phase of TB treatment: Rifampicin 75mg + Isoniazid 50 mg + Pyrazinamide 150mg – WHO PQ on 12 December 2017
- For the continuation phase of TB treatment: Rifampicin 57mg + Isoniazid 50mg – WHO PQ on 31 August 2017
This information is reflected on the website of World Health Organization (WHO) here. The link leads to a database. The child-friendly TB FDCs are numbers: TB302 (for the continuation phase) and TB309 (for the intensive phase).